Recombinant Interferon Alfa 2A in Hepatic Hemangiomatosis with Congestive Heart Failure: A Case Report

Schiavetti, Amalia; Pasquale, Maria Debora De; Salvo, S. Di; Ventriglia, Flavia; Clerico, A.

doi:10.1080/0880010390158676

Cited by 10 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For symptomatic patients and/or hemangiomas larger than 5cm, several approaches had been studied. Non-surgical options included hepatic arterial embolization, [8] radiation [9], or interferon alpha-2a [10]. Enucleation was currently the preferred surgical treatment, followed by liver resection [4].…”

Section: Discussionmentioning

confidence: 99%

Pedunculated Hepatic Hemangiomas often Misdiagnosed Despite Their Typical Findings

Ha¹

2013

TOSJ

View full text Add to dashboard Cite

Abstract:Background: Hepatic hemangiomas are the most common benign liver tumors which can be often diagnosed radiologically. However despites their typical radiologic findings, giant pedunculated hemangiomas are rare and often misdiagnosed as a supra-renal, retroperitoneal, gastric, or mesenteric mass. Methodology:The authors present a case and the summary of a thorough literature search on this rare disease entity.Results: A 35-year-old male is found to have a 12cm mesenteric mass on computed tomography and undergoes a surgical exploration. Intraoperatively, a large pedunculated hepatic hemangioma from the left lobe of the liver is encountered and removed successfully. A thorough PubMed search reveals a total of 18 publications in English with 24 cases of giant pedunculated hepatic hemangioma, most of which occur in older females, and originate from the left lobe of the liver. These tumors in general retain the typical computed tomography or magnetic resonance imaging findings of an intrahepatic hemangioma.Conclusions: When a peri-hepatic lesion possesses typical radiologic characteristics of a hemangioma, pedunculated hemangioma should be included in the differential diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pedunculated Hepatic Hemangiomas often Misdiagnosed Despite Their Typical Findings

Ha¹

2013

TOSJ

View full text Add to dashboard Cite

show abstract

“…Duration of haemangiomas treatment by subcutaneous administration ranges from 3.5 to 10 months [13][14][15][16] in which we must also consider the number of injections the patient is subjected, that make him and his parents fill extremely uncomfortable. By intralesional administration, 81.25% of the patients reached the satisfactory regression limit in a mean value of 2 months period, a duration that is extremely smaller than other methods of INF-A application.…”

Section: Discussionmentioning

confidence: 99%

Intralesional administration of interferon A for the management of severe haemangiomas

et al. 2006

View full text Add to dashboard Cite

Intralesional administration of interferon alpha (INF-A) is a new approach in haemangiomas treatment that we electively apply to our patients. The aim of this study is to report the beneficial results of this new kind of therapy. Thirty-two patients with severe haemangiomas, 19 females and 13 males, were treated at our department from January 2000 to December 2004. All patients received INF-A intralesionally at a dose of 1-3 MIU/m(2) of body surface once a day for the first week, and then once a week until completion of therapy. Reduction was evaluated after clinical and radiological measurement before, during and after completion of therapy and was graded as complete (>80%), significant (50-80%), medial (20-50%) and no response (<19%). Mean duration of therapy was 8 weeks (2 months). Most patients had not received prior therapy. Complete regression was noticed in 18 patients, satisfactory in 8 patients, minimal in 4 and no response in 2 patients. Minimal complications such as flu-like malaise with fever were reported by 23 patients at the beginning of therapy, but it was resolved easily by paracetamol administration. Complications such as haemorrhage or allergic reaction during administration or neurological symptoms were not reported or noticed. Intralesional administration of interferon A can be considered as a safe option for the management of massive or life-threatening haemangiomas as it requires reduced duration of treatment; hence this option results in reduced financial cost, is well tolerated by patients and is free of major complications.

show abstract

“…rh‐IFNα2a can inhibit virus entry into cells, prevent viral protein translation and viral particle assemble, induce cell production of antiviral protein and promote T‐lymphocyte differentiation, enhance macrophage activity, regulate NK cell activity and suppress cell division. rh‐IFNα2a has been successfully applied in clinical practice as therapy for renal cell carcinoma, melanoma, lymphoma and breast cancer . Unfortunately, the approaches for cancer treatment are constantly challenged by poor selectivity and limited access to neoplastic cells, which not only lead to a dose‐limiting effect on the tumour region, but also have side effects on healthy tissues.…”

Section: Introductionmentioning

confidence: 99%

Comparative pharmacokinetics of a tumour-targeting therapy candidate rh-IFNα2a–NGR with rh-IFNα2a administered intravenously in mice and rats

Wang

Song

et al. 2013

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

Recombinant Interferon Alfa 2A in Hepatic Hemangiomatosis with Congestive Heart Failure: A Case Report

Cited by 10 publications

References 11 publications

Pedunculated Hepatic Hemangiomas often Misdiagnosed Despite Their Typical Findings

Pedunculated Hepatic Hemangiomas often Misdiagnosed Despite Their Typical Findings

Intralesional administration of interferon A for the management of severe haemangiomas

Comparative pharmacokinetics of a tumour-targeting therapy candidate rh-IFNα2a–NGR with rh-IFNα2a administered intravenously in mice and rats

Contact Info

Product

Resources

About